Roche: No Major M&A Needed To Offset Biosimilar Threat
Rather than buying its way out of trouble, Roche is backing its new products, notably the multiple sclerosis drug Ocrevus, the PD-L1 inhibitor Tecentriq and the lung cancer treatment Alecensa to offset the battering from biosimilar competition to some of its big-selling cancer therapies.
You may also be interested in...
Following tax reform, analysts expect imminent biopharma mega-mergers, with Pfizer, Merck and Roche looking to buy, AstraZeneca, Bristol and Vertex looming as take-out candidates, and Amgen as either a buyer or a target.
Roche has continued to drip-feed results from the IMmotion151 Phase III study, this time describing the magnitude of the beneficial responses observed with the first-line use of the Tecentriq-Avastin combination in patients with advanced renal cell cancer.
Top-line results from Roche's Phase III IMmotion151 study indicates the first-line use of a Tecentriq-Avastin combination has a significant effect on patients with advanced renal cancer who are PD-L1 expressers, but further details from the study will only become available in 2018.